The FDA has granted approval to two generic versions of  extended-release oxybutynin chloride for the treatment of overactive bladder.  Mylan Laboratories received final approval for 5- and 10-mg extended-release  tablets, and IMPAX Laboratories received approval for 15-mg extended-release  tablets. Both companies said the products would be launched immediately.

News

The FDA has granted approval to two generic versions of extended-release oxybutynin chloride for the treatment of overactive bladder.